Ital­ian AAV biotech clos­es $65M Se­ries A; GSK's Jem­per­li nabs pri­or­i­ty re­view in en­dome­tri­al can­cer

AA­Vant­garde, a Mi­lan-based AAV biotech, has closed a €61 mil­lion ($65.1 mil­lion) Se­ries A round.

The biotech cur­rent­ly has two AAV plat­forms, one us­ing DNA re­com­bi­na­tion and an­oth­er that trans-splices pro­teins, with treat­ment tar­gets in oph­thal­mol­o­gy. AA­Vant­garde is seek­ing to val­i­date its two lead plat­forms, tag­ging the funds for a proof-of-con­cept study and fur­ther de­vel­op­ment.

“This fi­nanc­ing rep­re­sents a hall­mark mo­ment in our mis­sion to help pa­tients and we are ex­cit­ed to work with both our new and found­ing in­vestors to ad­vance our plat­forms and pipeline. The com­ple­tion of this round with such a high-cal­iber group of glob­al life sci­ence in­vestors is a recog­ni­tion of the sig­nif­i­cance of AA­Vant­garde’s unique tech­nol­o­gy, which will ini­tial­ly be uti­lized to help pa­tients suf­fer­ing with the de­bil­i­tat­ing im­pact of blind­ness as­so­ci­at­ed with Ush­er1B syn­drome and Star­gardt dis­ease,” CEO Na­talia Mis­ci­at­tel­li said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.